Document hub

Our international presence

Return to Hikma.com
Contact Us

Popular searches

What we do

We bring patients across North America, MENA and Europe a broad range of generic, specialty and branded pharmaceutical products.

We have three distinct businesses that enable us to create high-quality medicines and make them accessible to those who need them.

We have 30 manufacturing plants, 9 R&D centres and c.9,100 employees worldwide, manufacturing and supplying over 760 products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

Learn more about what we do

Injectables

We are the third largest supplier of generic injectables in the US [1]. We supply hospitals across our markets with generic injectable products, supported by our manufacturing facilities in the US, Europe and MENA.

Branded

We are the second largest pharmaceutical company in MENA. We supply branded generics and in-licensed patented products from our local manufacturing facilities to retail and hospital customers across the MENA region.

Generics
We supply oral and other non-injectable generic and specialty branded products to the US retail market, leveraging our state-of-art manufacturing facility in Columbus, Ohio.
Our three businesses in numbers
$ 1,203 m Injectables 2023 revenue
$ 714 m Branded 2023 revenue
$ 937 m Generic 2023 revenue

Discover more

Operations
Partnering with Hikma
Contract manufacturing

1. IQVIA MAT May 2023, generic injectables by volume (excluding branded generics and Becton Dickinson).
2.Based on internal analysis by Hikma using IQVIA MIDAS® Monthly value sales data for Kuwait, KSA, UAE, Jordan, Lebanon, Egypt, Tunisia, Algeria and Morocco, MAT Dec 2023, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved.

Number of products as of February 2024.